A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled
prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus
placebo/control in subjects with AIS.